Spinal Muscular Atrophy Treatment Market - Top Companies and Manufacturers

Companies Dominating the Spinal Muscular Atrophy Treatment Landscape

Companies in the spinal muscular atrophy treatment market are focusing on offering more effective long-term solutions. Many are investing in personalized medicines, targeting specific genetic mutations, while others are enhancing patient access through pricing strategies, reimbursement partnerships, and early screening programs. In October 2024, Roche presented two-year positive data from the ongoing study RAINBOWFISH at the 29th World Muscle Society assessing the efficacy and safety of risdiplam in children with SMA. Gaining regulatory approvals, and entering new markets are also a key strategy adopted by the prominent players.

• American Physical Therapy Association
  • Company Overview
  • Business Strategy
  • Key Product Offerings
  • Financial Performance
  • Key Performance Indicators
  • Risk Analysis
  • Recent Development
  • Regional Presence
  • SWOT Analysis
• Astellas Pharma
• Beijing Jinlan Gene Technology Co., Ltd.
• Biogen Inc.
• Boston's Children Hospital
• Children's Hospital of The King's Daughters
• F. Hoffmann-La Roche Ltd.
• Hanugen Therapeutics
• Nationwide Children’s Hospital
• NMD Pharma A/S
• Novartis AG
• Pfizer, Inc.
• Scholar Rock, Inc.